Multinational multicohort phase 1 trial of zongertinib for previously treated HER2-mutant non-small lung cancer
Prof. John Heymach
Innovative oral targeted therapies are warranted for patients with HER2-mutant non-small cell lung cancer. Zongertinib is an oral, irreversible, HER2-selective tyrosine kinase inhibitor. The multinational phase 1a-1b Beamion LUNG-1 trial, presented today at the Annual Meeting of AACR, found that zongertinib showed clinical benefit with mainly low-grade adverse events in patients with previously treated HER2-mutant NSCLC.
